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therapy, 2) to evaluate the effect of antibiotic resistance on the treatment outcome and 3)
to elucidate other causes of eradication failure for this triple therapy. Methods: Helicobacter
pylori-positive 155 patients by culture were assigned to 7-days eradication therapy with
lansoprazole 30 mg b.i.d., amoxicillin 750 mg b.i.d., and metronidazole 250 mg b.i.d.
The outcome of eradication was assessed by 13C urea breath test. Minimum inhibitory
concentration (MIC) of clarithromycin, amoxicillin or metronidazole were retrospectively
investigated for H. pylori isolates from all patients by agar dilution method. The relationship
between eradication failure and the patients' background (age, gender, drinking, smoking,
number of previous eradication attempt, and antimicrobial resistance of the isolated strain)
were analyzed. Results: After eradication treatment, 150 patients returned to the physician
and were evaluated for the outcome from therapy by 13C urea breath test. Fifteen patients
were posistive for H. pylori, including one patient who failed to complete the medication
because of diarrhea. No other severe adverse event was reported. The eradication rate was
90.3% (140/155) by intention-to-treat analysis and 94.0% (140/149) by per-protocol analysis.
Antimicrobial resistant strains were isolated from one patient for amoxicillin, from 58 for
clarithromycin and from eight for metronidazole. Six patients with metronidazole-resistant
strains were successfully eradicated and no significant effect on eradication rate by antibiotic
resistance was observed. The risk of eradication failure was significantly related only to the
number of previous treatment failure with odds ratio of 2.62 (1.09-6.25, 95% confidence
interval) by one previous failure. Conclusions: The triple therapy with lansoprazole, amoxicil-
lin, and metronidazole is safe and effective regardless of MIC of the isolated strains in Japan.
However, eradication therapies after two or more failed attempts are at risk of another
failure, which is unrelated to the resistance of the strains.
M1090
Rifabutin Resistance of H. pylori Isolated from Japanese Patients
Shoji Suzuki, Hidekazu Suzuki, Toshihiro Nshizawa, Fumihiko Kaneko, Yoshimasa Saito,
Sumire Ootani, Hiroe Muraoka, Intetsu Kobayashi, Mamoru Miyairi, Toshifumi Hibi
Background and Aim. Recently, the number of Helicobacter pylori (H. pylori) isolates showing
antibiotic resistance has been increasing. Rifabutin, although not currently available in Japan,
is reported to be one of the candidate components of a new regimen for H. pylori eradication
(Antimicrob Agents Chemother 43:1497-1499, 1999). Rifabutin is an antituberculosis agent
derived from rifamycin-S. In the present study, the MICs of rifabutin and the resistance-
determining genes to rifabutin were examined using strains isolated from patients in two
different types of hospitals in Japan, in order to clarify the relationship between the MICs
of the drug and the presence of mutations of the resistance-determining gene in the isolates.
Methods. The MICs of rifabutin were examined for 48 strains of H. pylori isolated from the
patients of a general hospital (Keio University Hospital) and 46 strains isolated from the
patients at a specialized hospital for chronic respiratory diseases (National Minami-Yokohama
Hospital), and the isolates were examined for the presence of point mutations of rpoB.
Results. Although 3 of the 48 strains (6.3%) isolated from patients in Keio University Hospital
showed point mutations (V538I) of the rpoB gene, the MICs of rifabutin were low for all
of the 48 strains (MIC<0.015). On the other hand, seven of the 46 strains (15.2%) isolated
from the patients at National Minami-Yokohama Hospital showed point mutations in the
resistance-determining regions of the rpoB gene of rifabutin, and the MICs of rifabutin were
high (MIC > 0.5) for five of these seven strains (71.4%) with point mutations in the rpoB
gene (PPV: 71.4%, NPV: 97.7%, sensitivity: 71.4%, speciality: 97.7%, p<0.001). In particular,
the MICs were high for strains isolated from patients with a past history for treatment with
rifampicin (PPV: 85.7%, NPV: 98.9%, sensitivity: 85.7%, speciality: 98.9%, p<0.001). And,
the relationship between the MICs of RBU (more than 0.015µg/ml) and RFP for the strains is
a significant linear correlation. Conclusion. Although rifabutin might be a potential candidate
component of a new regimen for H. pylori eradication therapy following failure of the first-
line and/or second-line regimens, it should be used only after the patient is checked for a
past history of treatment with rifampicin.
M1091
Ten-Day Sequential Therapy Is Superior to Triple Therapy for the Eradication
of Helicobacter pylori: Systematic Review and Meta-Analysis
Luigi Gatta, Dino Vaira, Nimish Vakil
Background: The success of the current recommended therapy for H pylori infection (PPI-
triple therapy) has declined to unacceptable levels. Sequential therapy is a novel treatment
strategy that has shown promise in several controlled. Aim: To perform a systematic review
and meta-analysis to determine the therapeutic efficacy of sequential therapy compared to
the PPI-triple therapy in adults and children. Data Sources: Studies were identified by
searching the Cochrane Trial Register (Issue 3, 2007), MEDLINE (1966 - September 2007),
EMBASE (1980-September 2007), two register trials, and abstracts from the major US
and European gastroenterology conferences. Study Selection: Randomized controlled trials
comparing sequential therapy to PPI- triple therapy in adults and children H pylori infected.
Data Extraction: Two investigators separately performed the search, selected the studies,
and jointly performed data extraction. Quality assessment was performed using a scale
described by Jadad. A third investigator arbitrated in the event of a lack of agreement. Sub-
group analyses were performed evaluating: age of patients, duration of triple therapy, Jadad
score, presence of NUD or PUD, number of tests performed to confirm the eradication.
Results: 7 randomized controlled trials enrolled adult patients and the pooled relative risk
for eradication of H pylori with sequential therapy compared to triple therapy was 1.22
(95% CI 1.18 to 1.26; I2= 0%) with a number needed to treat of 6 (95% CI: 5 to 7). 2
studies enrolled children and adolescents, and the pooled relative risk for eradication of H
pylori with sequential therapy compared to triple therapy was 1.21 (95% CI 1.04 to 1.40;
I2= 0%) with a number needed to treat of 6 (95% CI: 4 to 26). Conclusion: Sequential
therapy is superior to triple therapy in the eradication of H pylori. It should be evaluated
further as a potential new first-line therapy in infected patients
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M1092
A Randomized Double Blinded Clinical Trial with Omeprazole, Levofloxacin
and Escalated Dose of Rifaximin for Helicobacter pylori in Treatment-NaïVe
Population
P. Patrick Basu, Krishna Rayapudi, Jose Estevez
Purpose: Helicobacter pylori(H pylori) is an insidious infection with a significant progression
to gastric carcinoma, lymphoma,peptic ulcer disease and is a WHO class 1 carcinogen.Preval-
ence was estimated at about 70% in developing countries and 30-40% in the United States.
Resistance to currently used drugs{eg.,Metronidazole (28.9%),Clarithromycin(10.9%) and
Amoxicillin (12%)}is a limiting factor in treatment.Tripe therapy with Clarithromycin,Amox-
icillin and a Proton Pump Inhibitor (PPI)has been the gold standard.Rifaximin and Levoflox-
acin were used individually with success in various clinical trials as salvage therapy for
recurrent H pylori.Our prior experience with this novel regime of Rifaximin 400mg,Omepra-
zole 20mg and Levofloxacin 250mg twice daily as first line therapy for eradication of H
pylori in the treatment-naïve population had 50% efficacy.So we proposed a similar double
blinded randomized trial with increased dose of Rifaximin(for better efficacy) and same dose
of Levofloxacin and Omeprazole, all for ten days. Methods: Patients with dyspepsia were
evaluatedwith upper endoscopy,biopsy and stool antigen testing for H pylori(Quest Diagnost-
ics Inc,Teterboro,NJ).Thirty patients of diverse ethnic background with stool antigens positive
for H pylori and confirmed histologically were randomized in a double blinded fashion in two
arms.Patients with use of PPI,Non-Steroidal Anti-Inflammatory Drugs,Aspirin or antibiotics in
4 weeks preceding detection of H pylori were excluded.One arm(n=15)was treated with
Rifaximin 600mg, Omeprazole 20mg and Levofloxacin 250mg all twice daily for 10 days
and the other arm(n=15) with Rifaximin 800 mg,Omeprazole 20 mg, and Levofloxacin
250mg all twice daily for same duration.Follow up stool testing for H pylori antigen was
performed after cessation of Omeprazole for atleast 2 weeks. Results: 6 patients(40%) and
8 patients(53%) cleared H pylori in the 600mg Rifaximin and 800mg Rifaximin arms
respectively.10 patients(33%) experienced mild to moderate side events but completed the
full course. Conclusion: There is no statistically significant benefit with escalated doses of
Rifaximin for eradication of H pylori. These regimes' eradication rate compared with 50%
in our earlier study using 400mg of Rifaximin twice daily.Cost benefit analysis of higher
doses do not justify this strategy for initial treatment.We foresee no added therapeutic or
economic benefit with this combination in naive or salvage therapy in future.
M1093
Levofloxacin- and Amoxcillin-Based Quadruple Therapy for the Third-Line
Treatment of Helicobacter pylori Infection
Ping-I Hsu, Deng-Chyang Wu
Background: A standard third-line therapy for Helicobacter pylori (H pylori) infection is
lacking, and antimicrobial sensitivity data for patients failing eradication are often unavailable
in clinical practice. We therefore designed the prospective study to assess the efficacy of a
novel third-line levofloxacin- and amoxcillin-based quadruple therapy. Patients andmethods:
From September 2005 to August 2007, 42 consecutive H pylori-infected patients who had
failed standard first-line and second-line treatments underwent a 10-day quadruple therapy
comprising rabeprazole 20 mg b.d., bismuth subcitrate 300 mg q.d.s., amoxicillin 500 mg
q.d.s., and levofloxacin 500 mg o.d. Follow-up endoscopy with rapid urease test, histological
examination and culture was performed at six weeks after the end of treatment to evaluate
the response to therapy. Results: H pylori was successfully eradicated in 37 out of 42 patients
(88% by both intention-to-treat analysis and per-protocol analysis). All patients (100%)
complied with the eradication therapies, and only nine (21%) patients complained of mild-
to-moderate adverse events. Amoxicillin- and levofloxacin-resistant strains were observed
in 17% and 22% clinical isolates, respectively. There were no significant differences between
H pylori eradication rates and antibiotic resistances. Conclusions: The 10-day levofoxacin-
and amoxicillin-based quadruple therapy is well tolerated and achieves a high eradication
rate in third-line empirical treatment for H pylori infection.
M1094
Increased Prevalence of Helicobacter pylori 23s rRNA Gene Mutations in
Patients with Gastritis in Pakistan
Javed Yakoob, Wasim Jafri, Zaigham Abbas, Shahab Abid, Rustam Khan, Nida Jafri,
Zubair Ahmad
Background The major cause of Helicobacter pylori treatment failure is clarithromycin resist-
ance which is attributed to point mutations within the peptidyltransferase-encoding region
in domain V of the 23SrRNA gene. Several distinct point mutations including A2142G,
A2143G, A2142C, A2115G and G2141A have been described. Aims: The aim of this study
was to determine the prevalence of clarithromycin point mutations A2142G, A2143G and
A2142C in patient presenting with H. pylori associated nonulcer dyspepsia, gastric and
duodenal ulcer and gastric carcinoma and lymphoma. Methods PCR-restriction fragment
length polymorphism (PCR-RFLP) was used to allow the identification of mutations A2142G
and A2143G using the BbsI and BsaI restriction enzymes, respectively and for detection of
mutation A2142C using the enzyme BceAI A 267-bp fragment was amplified by PCR using
primers 5_-AGGTTAAGAGGATGCGT CAGTC-3 (HPY-S) and 5- CGCATGATATTCCCAT-
TAGC AGT-3 (HPY-A), corresponding to nucleotides 1931 to 1952 and 2197 to 2175,
respectively, of the 23S rRNA gene of H. pylori. Differences in proportion were assessed by
using Pearson Chi square, Fisher exact or likelihood ratio test where appropriated. P value
less than 0.05 was considered as statistical significant, all p value were two sided. Result:
There were 55 (59%) males. Abdominal pain was present in 79(85%). CLR mutation was
present in 34 (37%) patients. Mutations were common in patients with symptoms p=0.008.
Endoscopically, antral gastritis was present in 32(34%), pangastritis 34(37%), gastric ulcer
7(8%), gastric carcinoma 15(16%) and duodenal ulcer in 5(5%). Histology showed acute
on chronic inflammation in 57(62%), chronic inflammation 18(19%), gastric adenocarcinoma
15(16%) and lymphoma 3 (3%), respectively. Helicobacter pylori was positive on histology
in 74(80%) and H. pylori glmM PCR in 93(100%) patients. CLR mutations were significantly
present in patients with gastritis 30(88%) as compared to gastric carcinoma 1(3%) and
peptic ulcers 3(9%) (p=0.02). On histology, 24 (71%) patients with chronic active gastritis
had CLR mutations compared to 10 (29%) with chronic inflammation and gastric carcinoma
and lymphoma 1(3%) (p= 0.004). Conclusion: Clarithromycin mutations were present in
clinical isolates of H. pylori. They were significantly associated with endoscopic gastritis with
chronic active gastritis compared to peptic ulcer and gastric carcinoma.
M1095
Empirical Rescue Therapy After H. pylori Treatment Failure: A 10-Year Single
Center Study of 500 Patients
Javier P. Gisbert, Jose-Luis Gisbert, Eusebio Marcos, Isabel Jimenez-Alonso, Adrian G.
McNicholl, Ricardo Moreno-Otero, Jose-Maria Pajares
BACKGROUND: The most commonly used first-line eradication therapies may fail in up to
20-30% of patients. Several “rescue” therapies have been recommended, but they still fail
to eradicate H. pylori in more than 20% of the cases. Currently, a standard third-line therapy
is lacking, and international guidelines recommended culture in these patients to select a
third-line treatment according to microbial sensitivity to antibiotics. However, cultures are
often carried out only in research centers, and the use of this procedure as “routine practice”
in patients who failed several treatments is not feasible. AIM: To evaluate the efficacy of
different “rescue” therapies empirically prescribed (antibiotic susceptibility was unknown)
during 10 years to 500 patients in whom at least one eradication regimen had failed to cure
H. pylori infection. METHODS: Design: Prospective single-center study. Patients: Consecutive
patients in whom at least one eradication regimen had failed. Intervention: Rescue regimens
included: 1) Quadruple therapy with omeprazole-bismuth-tetracycline-metronidazole; 2)
ranitidine bismuth citrate-tetracycline-metronidazole; 3) omeprazole-amoxicillin-levoflox-
acin; and 4) omeprazole-amoxicillin-rifabutin. Antibiotic susceptibility was unknown (rescue
regimens were chosen empirically). Outcome: Eradication was defined as a negative 13C-
urea breath test 4-8 weeks after completing therapy. RESULTS: Five-hundred patients were
included (76% functional dyspepsia, 24% peptic ulcer). Compliance with 2nd, 3rd, and
4th-line regimens was 92%, 92%, and 95%. Adverse effects were reported by 30%, 37%,
and 55% of the patients receiving 2nd, 3rd, and 4th-line regimens. Overall, H. pylori cure
rates with the 2nd, 3rd, and 4th-line rescue regimens were 70%, 74%, and 76%. Cumulative
H. pylori eradication rate with 4 successive treatments was 99.5%. CONCLUSION: It is
possible to construct an overall treatment strategy to maximize H. pylori eradication, based
on the administration of four consecutive empirical regimens; thus, performing bacterial
culture even after a second or third eradication failure may not be necessary.
M1096
High Dose vs. Standard Dose Proton Pump Inhibitor Triple Therapy for
Helicobacter pylori Eradication: A Meta-Analysis
Albert Villoria, Xavier Calvet, Pilar Garcia, Javier P. Gisbert, Valentí Puig Diví
Introduction: The usefulness of using high-dose proton pump inhibitor (PPI) in triple therapy
for H. pylori eradication is controversial. Objective: To review the evidence on the possible
usefulness of high dose PPI in standard triple therapy for Helicobacter pylori eradication.
Methods: A systematic search was performed in multiple databases (MEDLINE, ISI Web of
Knowledge, Embase, Cochrane Database of Randomized trials and CINAH), and in the
abstracts submitted to the Digestive Diseases Week and the European Helicobacter Study
Group congresses between 2000-2007. The references of the relevant articles or reviews were
also assessed. Randomized trials comparing a standard dose PPI (omeprazole, rabeprazole or
esomeprazole 20 mg, lansoprazole 30 mg or pantoprazole 40 mg) twice a day with high
dose PPI (esomeprazole, rabeprazole or omeprazole 40mg, lansoprazole 60mg or pantoprazol
80 mg) twice a day in triple therapy, strategies combining a PPI plus clarithromicyn and
either amoxicillin or metronidazole were selected. Results: Six studies including 1703 patients
fulfilled the inclusion criteria. All of them used triple therapy for 7 days. High dose PPI
achieved a mean intention to treat cure rate of 82.5% vs. 73.9% with standard dose PPI
(RR 1.10, IC95%:1.02-1.19). Per protocol cure rate analysis was performed in 5 studies;
respective cure rates were 89.5% and 82.9%, (RR 1.08, IC95%:1.03-1.13). No statistically
significant difference was found between both groups in terms of side effects. Conclusion:
High dose PPI increase H. pylori eradication cure rates in triple therapy when compared
with currently used standard dose.
M1097
Reflux Symptoms Worsen After Eradication of Helicobacter pylori in Japanese
Patients with Atrophic Gastritis
Haruka Kajiwara, Yutaka Yamaji, Noriyuki Takano, Takafumi Sugimoto, Atsuo Yamada,
Masao Akanuma, Goichi Togo, Keiji Ogura, Makoto Okamoto, Haruhiko Yoshida, Takao
Kawabe, Masao Omata
[Background]Eradication of Helicobacter pylori(HP) does not affect, or improve gastro-eso-
phageal reflux symptoms in Western people in whom HP causes antrum-predominant
gastritis. However, it may not be true in Japanese people whose gastritis is pangastritis or
corpus-predominant gastritis. [Objective]To evaluate whether the reflux symptoms worsen
or not after eradication of HP in Japanese patients. [Methods]A total of 175 patients with
HP received the eradication therapy. Reflux symptoms were assessed by using Gastrointestinal
Symptom Rating Scale (GSRS) before and three months after eradication. The sum of the
scores of heartburn and acid regurgitation was determined as reflux score graded from point
2 (none) to 14 (the most severe). Patients were classified into three groups according to the
change of reflux score after the eradication therapy; “Worsen”, “No change”, or “Improve”
groups when the reflux score increased, did not change, or decreased, respectively. The
successful eradication was judged by the urea breath test three months after eradication.
The change of reflux score was compared according to the success or failure of eradication.
Sex, age, pretreatment findings (ulcer, hiatal hernia, and the reflux score before eradication)
were evaluated as risk factors. [Results]The eradication was successful in 123 patients (70.3%)
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and 52 patients failed. In patients with successful eradication, the reflux scores worsened
in 29 patients (24%), did not change in 49 patients (40%), and improved in 45 patients
(36%). On the other hand, in patients with eradication failure, 4 patients were classified as
“Worsen” (8%), 22 “No change” (42%), and 26 “Improve” (50%). The rate of worsening of
the reflux scores was significantly higher in patients with successful eradication (p=0.02).
In a multivariate analysis including sex, age, and pretreatment findings, the eradication
success was judged as the only risk factor for the worsening of reflux scores (OR=4.1,
95%CI=1.3-12). In 29 patients with worsening of reflux scores after eradication, the increased
points of reflux score were evaluated. In 5 patients with hiatal hernia, the mean increased
reflux score was 2.2 points, which was higher than 1.4 points in 24 patients without hiatal
hernia (p=0.02). In 11 patients with some reflux symptoms (>2 points) before the eradication,
the change of score showed a higher tendency than those without pretreatment reflux
symptoms (1.7 points vs 1.3 points, p=0.17). [Conclusions]The reflux symptoms worsened
after HP eradication in Japanese patients. Hiatal hernia and pretreatment reflux symptoms
may be risk factors for more severe worsening of the reflux symptoms.
M1098
Increased Rates of Peptic Ulcer Disease (PUD) and Helicobacter pylori (HP)
Related Hospitalizations in U.S. Children: A 15 Year Analysis
Gayle D. Horvitz, William S. McRae, Sarah Talarico, Tejas R. Mehta, Nina R. Salama, Jana
Stockwell, Malinda Kennedy, Benjamin D. Gold
Background: Approximately 70-80% of primary PUD in adults is caused by Hp; an infection
primarily acquired during childhood. Population-based studies of PUD in adults show a
significant impact in hospitalized persons. PUD prevalence and epidemiology in US children
is poorly characterized. Methods: We analyzed the Pediatric Health Information System
(PHIS) database from 43 US pediatric hospitals to determine the prevalence of PUD, gastritis,
bleeding ulcers, and Hp infection in hospitalized children between the years 2002-2007.
Results were compared to our previous analyses from the PHIS database over the years
1992-2000. Results: There were 2,361,578 hospital discharges from 2002-2007 compared
to 2,052,743 from 1992-2000 (32 US pediatric hospitals included). The proportion of
discharged patients with diagnoses of PUD, gastritis, and Hp are shown in Table 1; overall
PUD prevalence increased significantly for this period. 1121 (0.047%) patients had a dis-
charge diagnosis of bleeding ulcers from 2002-2007. From 2002-2007, Hp infection was
associated with a greater number of children hospitalized with duodenal ulcer (DU; 16.5%)
than with gastric ulcer (GU; 6%). Of 1578 children with a diagnosis of Hp, 1191 (75.5%)
had a concurrent diagnosis of gastritis or duodenitis, 314 (19.9%) had a diagnosis of
gastrointestinal bleeding, 94 (6%) had a diagnosis of GU, and 178 (11.3%) had a diagnosis
of DU. Yearly percentages of total discharges significantly decline in PUD, and gastritis/
duodenitis plus Hp between 2004 and 2005 (p=0.005 and p=0.002 respectively), which
mirrors a decline in Hp (p=0.001) these same years. These discharge diagnoses increased
subsequently. Gender, race/ethnicity, and age all affected rates of discharges due to PUD,
gastritis or Hp. Discussion: Rates of discharge diagnoses of PUD, Hp, and gastritis have
increased significantly in hospitalized children over the past 15 years. The decline in Hp
seen in pediatric hospitals from 2004 to 2005 is similar to adult studies over the same
years. The cause for this temporary decrease in Hp-related discharge diagnoses is unclear.
Prospective studies are needed to ascertain the epidemiology of PUD and the impact of Hp
infection among children in outpatient populations. Future PHIS analyses will include
extensive demographic information and financial impact that PUD and associated complica-
tions have on the pediatric health system.
Table 1: Percentages of total discharges, PHIS
aOnly data from 1995-2000 is available; *p< 0.0001
M1099
Symptom Association During Impedance Testing (pH-MII) Is Not Useful in
Predicting Outcome After Fundoplication
Rachel Rosen, Phillip Levine, Paul D. Mitchell, Samuel Nurko
Background: Causal relationships between symptoms and gastroesophageal reflux are diffi-
cult to prove. Previous pilot data has suggested that the number of reflux events detected
by pH-MII may not predict outcome after fundoplication. The role of symptom association
in predicting outcome is unknown. The aim of the study was to assess if symptom indices
are useful to predict which patients will improve symptomatically after fundoplication.
Methods: Records for patients who underwent fundoplication with preceding pH-MII testing
between January 2002 and October 2007 were reviewed. 34 children were included in the
analysis. pH-MII tracings were blindly reviewed and the symptom index (SI) and the symptom
sensitivity index (SSI) were determined for each patient. Patients were categorized as improved
or not improved after surgery. Patients who improved were further classified as improved
from a gastrointestinal (GI) and/or respiratory (RESP) perspective. ROC curves were generated
to determine the utility of SI and SSI testing in predicting surgical outcome. Logistic regression
was performed to determine predictors of overall outcome. Results: 22 patients (65%)
experienced overall symptomatic improvement after fundoplication; 20/27 patients with GI
symptoms improved and 15/31 patients with respiratory symptoms improved. Mean symp-
tom indices (±std) are shown in Table 1. Area under the curve and p values for the ROC
curves are shown in Table 2; the SI and the SSI could not adequately determine who did
and did not improve after fundoplication. Furthermore, logistic regression revealed that
neurologic status, age at fundoplication, number of reflux events by impedance, pH probe
results and symptom indices were not predictive of fundoplication outcome (p>0.2). Conclu-
sions: The SI and SSI may not be useful tests for predicting symptomatic improvement
after fundoplication.
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